Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Variagenics buys abnormal deoxyribonucleic acid (DNA) cleaving technology:

This article was originally published in Clinica

Executive Summary

Privately-held Variagenics has acquired what the company describes as "fundamental technologies for the rapid identification of gene sequence variations", by purchasing almost all the assets of Avitech Diagnostics for an undisclosed sum. The technologies include the trademarked Variance Imaging technique for detecting all types of DNA mismatches based on identifying cleavage points. US company Variagenics says it will continue Avitech's alliance with Amersham Pharmacia Biotech which has the worldwide rights to commercialise Enzymic Mutation Detection, upon which Variance Imaging is based.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts